- Clinical Trials
- April 2024
- 60 Pages
Global
From €1942EUR$2,000USD£1,660GBP
- Drug Pipelines
- January 2019
- 40 Pages
Global
From €1457EUR$1,500USD£1,245GBP
- Report
- January 2022
- 200 Pages
Global
From €7284EUR$7,500USD£6,223GBP
- Report
- January 2022
- 60 Pages
Global
From €3836EUR$3,950USD£3,278GBP
- Report
- February 2021
- 120 Pages
Global
From €2428EUR$2,500USD£2,074GBP
- Report
- April 2022
- 60 Pages
Global
From €1942EUR$2,000USD£1,660GBP
- Drug Pipelines
- August 2020
- 63 Pages
Global
From €1942EUR$2,000USD£1,660GBP
- Report
- July 2020
- 100 Pages
Global
From €4657EUR$4,795USD£3,979GBP
- Report
- January 2024
- 98 Pages
Global
From €3500EUR$3,860USD£3,095GBP
Blepharitis is a common eye disorder that affects the eyelids and is characterized by inflammation, redness, and irritation. It is often caused by bacterial or fungal infections, allergies, or skin conditions. Treatment for blepharitis typically involves the use of topical medications, such as antibiotics, antifungals, and anti-inflammatory drugs. These medications are often used in combination with other treatments, such as warm compresses, lid scrubs, and eyelid hygiene.
The Blepharitis Drug market is a segment of the larger Optical Disorders Drugs market. It is composed of a variety of medications used to treat blepharitis, including antibiotics, antifungals, and anti-inflammatory drugs. These medications are available in both prescription and over-the-counter forms.
Some companies in the Blepharitis Drug market include Allergan, Bausch + Lomb, Merck, Novartis, Pfizer, and Santen Pharmaceuticals. Show Less Read more